Carrie Strom Biography and Net Worth

SVP of AbbVie

Carrie Strom is Senior Vice President, AbbVie, and President, Global Allergan Aesthetics and has served in this role since May 2020. Prior to joining AbbVie, Ms. Strom served as Senior Vice President of U.S. Medical Aesthetics at Allergan® beginning in May 2018, overseeing the aesthetic portfolio for the multi-billion dollar U.S. business. Previously, Ms. Strom was Vice President of Marketing, Plastic Surgery and Regenerative Medicine at Allergan and she was instrumental in the $2.8B acquisition and integration of LifeCell. Before Allergan, Ms. Strom spent over 10 years at Pfizer where she led marketing for a leading statin and held various other sales and marketing roles. Ms. Strom received a B.A. in Communications from the University of Colorado, Boulder. She is an advocate for women in business and is actively involved with the Girls Inc. organization. She serves on the board of directors for Octane in Southern California and is a member of the Komen Leadership Council in Orange County. At AbbVie, she is the executive chair of the PRIDE Employee Resource Group.

What is Carrie C. Strom's net worth?: The estimated net worth of Carrie C. Strom is at least $6.66 million as of February 21st, 2023. Ms. Strom owns 37,921 shares of AbbVie stock worth more than $6,658,169 as of December 21st. This net worth approximation does not reflect any other investments that Ms. Strom may own. Learn More about Carrie C. Strom's net worth.
How do I contact Carrie C. Strom?: The corporate mailing address for Ms. Strom and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Carrie C. Strom's contact information.
Has Carrie C. Strom been buying or selling shares of AbbVie?: Carrie C. Strom has not been actively trading shares of AbbVie over the course of the past ninety days. Most recently, Carrie C. Strom sold 28,541 shares of the business's stock in a transaction on Tuesday, February 21st. The shares were sold at an average price of $151.04, for a transaction totalling $4,310,832.64. Following the completion of the sale, the senior vice president now directly owns 37,921 shares of the company's stock, valued at $5,727,587.84. Learn More on Carrie C. Strom's trading history.
Who are AbbVie's active insiders?: AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.
Are insiders buying or selling shares of AbbVie?: During the last year, insiders at the sold shares 13 times. They sold a total of 737,381 shares worth more than $130,442,034.24. The most recent insider tranaction occured on December, 16th when SVP Kevin K Buckbee sold 1,800 shares worth more than $310,032.00. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.
Information on this page was last updated on 12/16/2024.

Carrie C. Strom Insider Trading History at AbbVie

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/21/2023	Sell	28,541	$151.04	$4,310,832.64	37,921
2/7/2022	Sell	2,396	$141.17	$338,243.32
8/23/2021	Sell	5,057	$120.00	$606,840.00	11,595
5/3/2021	Sell	4,184	$112.40	$470,281.60	63,409

Carrie C. Strom Buying and Selling Activity at AbbVie

AbbVie Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Today's Range

Now: $175.58

$170.66

$176.80

50 Day Range

MA: $182.56

$164.91

$203.87

2 Week Range

Now: $175.58

$151.29

$207.32

Volume

17,695,750 shs

Average Volume

5,604,020 shs

Market Capitalization

$310.27 billion

P/E Ratio

60.97

Dividend Yield

3.54%

Beta

0.58

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.